» Articles » PMID: 36248857

Cuproptosis Regulator-mediated Patterns Associated with Immune Infiltration Features and Construction of Cuproptosis-related Signatures to Guide Immunotherapy

Overview
Journal Front Immunol
Date 2022 Oct 17
PMID 36248857
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Liver hepatocellular carcinoma (HCC) is a prevalent cancer that lacks a sufficiently efficient approach to guide immunotherapy. Additionally, cuproptosis is a recently identified regulated cell death program that is triggered by copper ionophores. However, its possible significance in tumor immune cell infiltration is still unclear.

Methods: Cuproptosis subtypes in HCC were identified using unsupervised consensus cluster analysis based on 10 cuproptosis regulators expressions, and a cuproptosis-related risk signature was generated using univariate and LASSO Cox regression and validated using the ICGC data. Moreover, the relationship between signature and tumor immune microenvironment (TME) was studied through tumor immunotherapy responsiveness, immune cell infiltration, and tumor stem cell analysis. Finally, clinical specimens were analyzed using immunohistochemistry to verify the expression of the three genes in the signature.

Results: Two subtypes of cuproptosis regulation were observed in HCC, with different immune cell infiltration features. Genes expressed differentially between the two cuproptosis clusters in the TCGA were determined and used to construct a risk signature that was validated using the ICGC cohort. Greater immune and stromal cell infiltration were observed in the high-risk group and were associated with unfavorable prognosis. Elevated risk scores were linked with higher RNA stemness scores (RNAss) and tumor mutational burden (TMB), together with a greater likelihood of benefitting from immunotherapy.

Conclusion: It was found that cuproptosis regulatory patterns may play important roles in the heterogeneity of immune cell infiltration. The risk signature associated with cuproptosis can assess each patient's risk score, leading to more individualized and effective immunotherapy.

Citing Articles

Integrative Analysis of Cuproptosis-Related Mitochondrial Depolarisation Genes for Prognostic Prediction in Non-Small Cell Lung Cancer.

Lyu G, Dai L, Deng X, Liu X, Guo Y, Zhang Y J Cell Mol Med. 2025; 29(4):e70438.

PMID: 40008552 PMC: 11862892. DOI: 10.1111/jcmm.70438.


Orchestrated copper-loaded nanoreactor for simultaneous induction of cuproptosis and immunotherapeutic intervention in colorectal cancer.

Li J, Ma S, Lin Q, Wang Q, Zhong W, Wei C Mater Today Bio. 2024; 29:101326.

PMID: 39606425 PMC: 11600019. DOI: 10.1016/j.mtbio.2024.101326.


Cuproptosis, the novel type of oxidation-induced cell death in thoracic cancers: can it enhance the success of immunotherapy?.

Zhao R, Sukocheva O, Tse E, Neganova M, Aleksandrova Y, Zheng Y Cell Commun Signal. 2024; 22(1):379.

PMID: 39068453 PMC: 11282696. DOI: 10.1186/s12964-024-01743-2.


Mechanisms of cuproptosis and its relevance to distinct diseases.

Lou Q, Lai F, Li J, Mao K, Wan H, He Y Apoptosis. 2024; 29(7-8):981-1006.

PMID: 38824478 DOI: 10.1007/s10495-024-01983-0.


Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes.

Tian J, Meng J, Yang Z, Song L, Jiang X, Zou J Front Immunol. 2024; 15:1411161.

PMID: 38799437 PMC: 11116790. DOI: 10.3389/fimmu.2024.1411161.


References
1.
Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L . Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 2018; 50(4):370-380. DOI: 10.1093/abbs/gmy009. View

2.
Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View

3.
Ju H, Lu Y, Wu Q, Liu J, Zeng Z, Mo H . Disrupting G6PD-mediated Redox homeostasis enhances chemosensitivity in colorectal cancer. Oncogene. 2017; 36(45):6282-6292. PMC: 5684443. DOI: 10.1038/onc.2017.227. View

4.
Turecky L, Kalina P, Uhlikova E, Namerova S, KRIZKO J . Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr. 1984; 62(4):187-9. DOI: 10.1007/BF01731643. View

5.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View